Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for recurrent endometrial cancer: personalized combo therapy tested

NCT ID NCT04486352

Disease control Sponsor: Alliance Foundation Trials, LLC. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining targeted drugs with the immunotherapy atezolizumab can shrink tumors or slow cancer growth in people with endometrial cancer that has come back or persists. About 148 participants whose cancer has progressed after at least one prior treatment will receive therapy matched to their tumor's genetic markers. The goal is to improve response rates and delay progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 148 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2021

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Recurrent or persistent endometrial carcinoma which has progressed or recurred after at least 1, but no more than 2, prior lines of therapy. Prior hormonal therapies (e.g., tamoxifen, aromatase inhibitors) will not count toward the prior regimen limit. Chemotherapy given in conjunction with radiotherapy as a radiosensitizer will be counted as a systemic therapeutic regimen. * Measurable disease per RECIST 1.1 * Availability of a representative tumor specimen that is suitable for determination of biomarker status via central testing (F1CDx) OR If a patient has a prior F1CDx report from 1 September 2019 or later, those NGS results can be used to determine biomarker status as long as the tumor tissue used in the report was obtained within 5 years prior to prescreening and appropriate signed consent is obtained from the patient. * Life expectancy \> 12 weeks * Recovery from effects of recent radiotherapy, surgery, or chemotherapy Key Exclusion Criteria: * Endometrial tumors with the following histologies: squamous carcinomas, sarcomas * Other invasive malignancies within the last 5 years, except for non-melanoma skin cancer with no evidence of disease within the past 5 years AND localized breast cancer with previous adjuvant chemotherapy treatment for breast cancer completed \> 5 years ago * Synchronous primary invasive ovarian or cervical cancer * Have an active or history of autoimmune disease or immune deficiency * Have a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis based on a screening chest computed tomography (CT) scan * Active tuberculosis * Severe infections within 4 weeks * Have received therapeutic oral or IV antibiotic medication within 2 weeks, except prophylactic antibiotic medication * Have significant cardiovascular disease * Are administered treatment with a live attenuated vaccine within 4 weeks, or anticipation of need for such a vaccine during the course of the study * Have prior allogeneic bone marrow transplantation or solid organ transplant * History of treatment with systemic immunostimulatory agents (including but not limited to interferons, interleukin-2) within 4 weeks or 5 half-lives of the drug, whichever is longer, prior to initiation of study treatment * History of treatment with systemic immunosuppressive medications within 2 weeks except acute, low-dose, systemic immunosuppressant medications, corticosteroids for chronic obstructive pulmonary disease and asthma, or mineralocorticoids and low-dose corticosteroids for participants with orthostatic hypotension or adrenocortical insufficiency * Have a history or clinical evidence of any untreated CNS disease, seizures not controlled with standard medical therapy, or history of cerebrovascular accident (stroke), transient ischemic attack or subarachnoid hemorrhage within 6 months AFT-50A Specific Exclusion Criteria: ● Prior treatment with T-cell costimulating or immune checkpoint blockade therapies including, but not limited to, CD137 agonists, anti-PD-1, anti-PD-L1, and anti-CTLA-4 therapeutic antibodies Note: Additional study cohort specific inclusion and exclusion criteria may apply based on cohort assignment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrial cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrial carcinoma endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometrial cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Atlantic Health Systems/Morristown Medical Center

    ACTIVE_NOT_RECRUITING

    Morristown, New Jersey, 07960, United States

  • Baptist Memorial Hospital

    WITHDRAWN

    Memphis, Tennessee, 38120, United States

  • City of Hope Comprehensive Cancer Center

    ACTIVE_NOT_RECRUITING

    Duarte, California, 91010, United States

  • Dana Farber Cancer Institute

    ACTIVE_NOT_RECRUITING

    Boston, Massachusetts, 02125, United States

  • Duke University Cancer Center

    ACTIVE_NOT_RECRUITING

    Durham, North Carolina, 27710, United States

  • Englewood Health

    ACTIVE_NOT_RECRUITING

    Englewood, New Jersey, 07631, United States

  • Lifespan - Rhode Island Hospital

    ACTIVE_NOT_RECRUITING

    Providence, Rhode Island, 02903, United States

  • Maine Medical Center

    ACTIVE_NOT_RECRUITING

    Scarborough, Maine, 04074, United States

  • Medstar Georgetown Cancer Institute

    ACTIVE_NOT_RECRUITING

    Washington D.C., District of Columbia, 20007, United States

  • Mount Sinai Comprehensive Cancer Center

    ACTIVE_NOT_RECRUITING

    Miami Beach, Florida, 33140, United States

  • Nebraska Methodist Hospital

    ACTIVE_NOT_RECRUITING

    Omaha, Nebraska, 68114, United States

  • Providence Portland Cancer Institute

    ACTIVE_NOT_RECRUITING

    Portland, Oregon, 97213, United States

  • Roswell Park

    ACTIVE_NOT_RECRUITING

    Buffalo, New York, 14263, United States

  • UCSF Helen Diller Family Comprehensive Cancer Center

    ACTIVE_NOT_RECRUITING

    San Francisco, California, 94143, United States

  • University of Chicago

    ACTIVE_NOT_RECRUITING

    Chicago, Illinois, 60637, United States

  • University of Kansas Cancer Center

    ACTIVE_NOT_RECRUITING

    Westwood, Kansas, 66205, United States

  • University of Minnesota

    ACTIVE_NOT_RECRUITING

    Minneapolis, Minnesota, 55455, United States

  • University of Oklahoma Health Stephenson Cancer Center

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

  • University of Pittsburgh Medical Center

    ACTIVE_NOT_RECRUITING

    Pittsburgh, Pennsylvania, 15261, United States

  • Washington University School of Medicine Siteman Cancer Center

    WITHDRAWN

    St Louis, Missouri, 63110, United States

  • Weill Cornell Medicine

    ACTIVE_NOT_RECRUITING

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.